fosamprenavir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 38 Diseases   5 Trials   5 Trials   121 News 


12»
  • ||||||||||  fosamprenavir / Generic mfg.
    Journal:  Development and Evaluation of a Protease Inhibitor Antiretroviral Drug-Loaded Carbon Nanotube Delivery System for Enhanced Efficacy in HIV Treatment. (Pubmed Central) -  Jan 8, 2024   
    To achieve this, Fosamprenavir calcium (FPV), a prodrug of amprenavir known for inhibiting the proteolytic cleavage of immature virions, was selected as the protease inhibitor antiretroviral drug, and loaded onto COOH-MWCNTs using a direct loading method...The successful encapsulation, sustained drug release, and reduced toxicity make FPV-MWCNT a compelling candidate for enhancing the therapeutic efficacy of protease inhibitor antiretroviral drugs in the treatment of HIV. The developed delivery system holds great promise for future advancements in HIV treatment and paves the way for further research and development in the field of drug delivery utilizing carbon nanotube-based systems.
  • ||||||||||  amprenavir / Generic mfg.
    Preclinical, Journal:  Amprenavir inhibits pepsin-mediated laryngeal epithelial disruption and E-cadherin cleavage in vitro. (Pubmed Central) -  Aug 25, 2023   
    Amprenavir, at serum concentrations achievable provided the manufacturer's recommended dose of fosamprenavir for HIV, protects against pepsin-mediated cell dissociation, E-cadherin cleavage, and MMP dysregulation thought to contribute to barrier dysfunction and related symptoms during LPR. Fosamprenavir to amprenavir conversion by laryngeal epithelia, serum and saliva, and relative drug efficacies in an LPR mouse model are under investigation to inform development of inhaled formulations for LPR.
  • ||||||||||  Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Rescriptor (delavirdine mesylate) / ViiV Healthcare, Relenza (zanamivir) / GSK, Vaxart
    FDA event, Journal:  Drug repurposing of FDA-approved anti-viral drugs via computational screening against novel 6M03 SARS-COVID-19. (Pubmed Central) -  Jul 29, 2023   
    Fosamprenavir to amprenavir conversion by laryngeal epithelia, serum and saliva, and relative drug efficacies in an LPR mouse model are under investigation to inform development of inhaled formulations for LPR. In our study, we also observed the nucleotide sequence of protease protein consisting of 316 amino acid residues
  • ||||||||||  Rukobia (fostemsavir) / ViiV Healthcare, fosamprenavir / Generic mfg.
    Journal:  Validation of an LC-MS/MS method for quantitation of fostemsavir in plasma. (Pubmed Central) -  Mar 16, 2023   
    In our study, we also observed the nucleotide sequence of protease protein consisting of 316 amino acid residues In summary, the developed method has been successfully validated and pharmacokinetic parameters were demonstrated after oral administration of Fostemsavir to healthy rabbits.
  • ||||||||||  Journal:  Discovery of Novel HIV Protease Inhibitors Using Modern Computational Techniques. (Pubmed Central) -  Oct 28, 2022   
    HPS/002 and HPS/004 have been found to be most promising in terms of IC/percent inhibition (90.15%) of HIV-1 PR, in addition to their drug metabolism and safety profile. These hit candidates should be investigated further as possible HIV-1 PIs with improved efficacy and low toxicity through in vitro experiments and clinical trial investigations.
  • ||||||||||  fosamprenavir / Generic mfg.
    Journal:  A New, Rapid and Simple RP-HPLC Method for Stability Quantification of a Protease Inhibitor in Tablets. (Pubmed Central) -  Sep 10, 2022   
    The analyte peak was found to be adequately separated from degradation products generated during forced degradation studies. Thus, the proposed method was found to accurately indicate stability and was sufficient for routine quantitative analysis of fosamprenavir in coated tablets without interference from major degradation products and excipients.
  • ||||||||||  zidovudine / Generic mfg.
    PK/PD data, Review, Journal:  A Review on Pharmacokinetics properties of antiretroviral drugs to treat HIV-1 infections. (Pubmed Central) -  Jan 18, 2022   
    These drugs are Fuzeon, Selzentry, Complera, Epivir, Retrovir, Emtriva, Ziagen, Edurant, Intelence, Pifeltro, Sustiva, Viramune, Isentress, Genvoya, Tivicay, Reyataz, Prezista, Lexiva, Invirase, Aptivus etc. classified into five major classes: fusion inhibitors, Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Integrase Strand transfer inhibitors (INSTIs) and Protease inhibitors (PIs). This review may be helpful for the future development of potent antiretroviral drugs with improved pharmacokinetic properties.
  • ||||||||||  fosamprenavir / Generic mfg.
    Trial completion date, Trial primary completion date:  Lexiva for the Treatment of LPR (clinicaltrials.gov) -  Nov 22, 2021   
    P3,  N=104, Not yet recruiting, 
    This review may be helpful for the future development of potent antiretroviral drugs with improved pharmacokinetic properties. Trial completion date: Jun 2024 --> Mar 2024 | Trial primary completion date: Jun 2024 --> Jan 2024
  • ||||||||||  Prezista (darunavir) / J&J, Crixivan (indinavir sulfate) / Merck (MSD)
    Retrospective data, Review, Journal:  HIV Protease Inhibitors and Insulin Sensitivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) -  Nov 21, 2021   
    Darunavir and indinavir did not demonstrate any significant changes in insulin sensitivity...Atazanavir, fosamprenavir, and darunavir did not demonstrate any significant changes in insulin sensitivity, compared to the rest of the group...All patients newly diagnosed with HIV should have DM investigations before the start of ARVs and routinely. RCTs should focus on sub-Saharan Africa as the region is worst affected by HIV, but limited studies have been documented.
  • ||||||||||  Phase classification:  Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) -  Jun 10, 2021   
    P=N/A,  N=1578, Completed, 
    Based on this case, it is important to alert the medical community of this possible life-threatening drug-drug interaction between eplerenone and ritonavir-boosted protease inhibitor. Phase classification: P4 --> P=N/A
  • ||||||||||  fosamprenavir / Generic mfg.
    Trial completion date, Trial primary completion date:  Lexiva for the Treatment of LPR (clinicaltrials.gov) -  May 10, 2021   
    P3,  N=104, Not yet recruiting, 
    Phase classification: P4 --> P=N/A Trial completion date: Nov 2025 --> Jun 2024 | Trial primary completion date: Nov 2025 --> Jun 2024
  • ||||||||||  fosamprenavir / Generic mfg.
    PK/PD data, Journal:  Fosamprenavir with Ritonavir Pharmacokinetics During Pregnancy. (Pubmed Central) -  Feb 23, 2021   
    Amprenavir area under the curve exceeded the target for 6/8 (75%) in the 2 trimester; 18/28 (64%) in the 3 trimester; and 19/22 (86.4%) postpartum, and the trough concentrations (C) of amprevavir were 4-16 fold above the mean amprenavir-protein-adjusted IC of 0.146μg/mL. Although amprenavir plasma concentrations in women receiving ritonavir-boosted fosamprenavir were lower during pregnancy compared to postpartum, the reduced amprenavir concentrations were still above the exposures needed for viral suppression.
  • ||||||||||  Vistide (cidofovir) / Gilead
    Journal:  Identification of potential antivirals against SARS-CoV-2 using virtual screening method. (Pubmed Central) -  Feb 18, 2021   
    Furthermore, some approved structural analogues, such as Telbivudine, Tenofovir, Amprenavir, Fosamprenavir, etc., were predicted as similar drugs which may also be used for treating viral infections. We highly recommend these drug candidates as potential fighters against the deadly SARS-CoV-2 virus, and suggest in vivo trials for experimental validation of our findings.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs. (Pubmed Central) -  Oct 23, 2020   
    In addition, another 10 compounds from CAS COVID-19 antiviral candidate compounds dataset are also suggested by Molecular Complex Characterizing System with potential treatment for COVID-19. Our work provides a novel strategy for the repurposing and combinations of drugs in the market and for prediction of chemical candidates with anti-COVID-19 potential.
  • ||||||||||  Trial completion:  Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) -  Oct 13, 2020   
    P4,  N=1578, Completed, 
    Our work provides a novel strategy for the repurposing and combinations of drugs in the market and for prediction of chemical candidates with anti-COVID-19 potential. Active, not recruiting --> Completed
  • ||||||||||  Jakafi oral (ruxolitinib) / Novartis, Incyte, emricasan (IDN 6556) / Conatus, Novartis, fosamprenavir / Generic mfg.
    Clinical, Journal:  Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19). (Pubmed Central) -  Jul 22, 2020   
    In the following 15 years, CD4+ count remained 95%: CD4+ count remained >600 cells/µL with CD8+ count steadily 55%). While these findings are not yet ready for clinical translation, this report highlights the potential use of two bioinformatics technologies to rapidly discover existing therapeutic agents that warrant further investigation for established and emerging disease processes.
  • ||||||||||  fosamprenavir / Generic mfg.
    Journal:  Studies on the characterization and polymorphic stability of Fosamprenavir. (Pubmed Central) -  Jun 14, 2020   
    In studies of accelerated stability the techniques of DSC, PXRD and FTIR showed that Form I does not suffer phase change when submitted to controlled conditions of temperature and humidity. Moreover, HPLC and FTIR proved the chemical stability of this solid form of fosamprenavir, thus demonstrating its suitability for pharmaceutical purposes.
  • ||||||||||  fosamprenavir / Generic mfg.
    Journal:  The influence of gastric motility on the intraluminal behavior of fosamprenavir. (Pubmed Central) -  Jun 4, 2020   
    Mean plasma t values were 157 (± 72.0) and 73.3 (± 27.3) min after administration in MMC phase I and MMC phase II, respectively. The study clearly identified the time of oral drug intake relative to the interdigestive motility pattern as a possible source of variation in gastrointestinal drug behavior and absorption.
  • ||||||||||  fosamprenavir / Generic mfg.
    New P3 trial:  Lexiva for the Treatment of LPR (clinicaltrials.gov) -  May 12, 2020   
    P3,  N=104, Not yet recruiting, 
  • ||||||||||  Enrollment closed:  Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) -  Jan 14, 2020   
    P4,  N=1786, Active, not recruiting, 
    The study clearly identified the time of oral drug intake relative to the interdigestive motility pattern as a possible source of variation in gastrointestinal drug behavior and absorption. Recruiting --> Active, not recruiting
  • ||||||||||  Trial completion date, Trial primary completion date:  Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) -  May 20, 2019   
    P4,  N=1786, Recruiting, 
    Management strategies, including rational use of complex exams (such as, computed-tomography angiography), statins and antihypertensives, should be developed based on the distinct roles of antiretroviral use and of HIV infection itself on the progression to cardiovascular events. Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Jun 2019 --> Sep 2020
  • ||||||||||  fosamprenavir / Generic mfg.
    Phase classification:  Fosamprenavir Versus Other Protease Inhibitors (clinicaltrials.gov) -  Jun 9, 2017   
    P3b/4,  N=312, Completed, 
    Active, not recruiting --> Completed Phase classification: P3 --> P3b/4
  • ||||||||||  fosamprenavir / Generic mfg.
    Trial completion:  Fosamprenavir Versus Other Protease Inhibitors (clinicaltrials.gov) -  Jun 8, 2017   
    P3b/4,  N=312, Completed, 
    Phase classification: P3 --> P3b/4 No longer recruiting --> Completed
  • ||||||||||  fosamprenavir / Generic mfg.
    Trial completion, Phase classification:  Fosamprenavir Expanded Access (clinicaltrials.gov) -  Sep 12, 2016   
    P4,  N=85, Completed, 
    Trial primary completion date: Dec 2016 --> Aug 2017 No Longer Available --> Completed | Phase classification: P3 --> P4
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Enrollment closed, Trial primary completion date:  HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen (clinicaltrials.gov) -  Jun 10, 2016   
    P4,  N=44, Active, not recruiting, 
    No Longer Available --> Completed | Phase classification: P3 --> P4 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Nov 2016
  • ||||||||||  Selzentry (maraviroc) / ViiV Healthcare
    Phase classification, Combination therapy:  An Interaction Study to Assess Drug Levels in Healthy Adult Subjects (clinicaltrials.gov) -  Jan 30, 2016   
    P2,  N=45, Completed, 
    N=1300 --> 1786 Phase classification: P=N/A --> P2
  • ||||||||||  Selzentry (maraviroc) / ViiV Healthcare
    Trial completion, Trial primary completion date:  MARCHrenal: MARCH Renal Substudy (clinicaltrials.gov) -  Jan 21, 2016   
    P4,  N=76, Completed, 
    Phase classification: P=N/A --> P2 Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Dec 2015